NCT05571111撤回2 期
A Randomised, Assessor-blind, Active-controlled, Parallel-group, Dose-finding Trial to Investigate the Efficacy and Safety of FE 999302 for Triggering of Final Follicular Maturation in Women Undergoing Controlled Ovarian Stimulation
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Number of metaphase II (MII) oocytes
研究概览
简要总结
The primary purpose of this trial is to compare three different doses of FE 999302 with 250 µg OVITRELLE and 10,000 IU NOVAREL on oocyte maturity when administered as a single dose for final development of the oocytes in women undergoing controlled ovarian stimulation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 42 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Pre-menopausal women between the ages of 18 and 42 years. The subjects must be at least 18 years (including the 18th birthday) and no more than 42 years (up to the day before the 43rd birthday) when they sign the informed consent.
- •Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II or with partners diagnosed with male factor infertility, eligible for in vitro fertilisation (IVF) and/or intracytoplasmic sperm injection (ICSI) using fresh or frozen ejaculated sperm from male partner or sperm donor.
- •Infertility for at least 1 year before screening for subjects <35 years or for at least 6 months for subjects ≥35 years (not applicable in case of tubal or severe male factor infertility).
- •No more than two controlled ovarian stimulation cycles initiated, regardless outcome (taking exclusion criteria 3, 4, and 5 into account).
- •Regular menstrual cycles of 24-35 days (both inclusive), presumed to be ovulatory.
排除标准
- •Known polycystic ovary syndrome (PCOS) associated with anovulation or known endometriosis stage III-IV (American Society for Reproductive Medicine, 2012).
- •Considered unsuitable for controlled ovarian stimulation with a starting dose of 150 or 225 IU/day highly purified human menopausal gonadotropin (HP-hMG), as judged by the investigator.
- •Poor response in a previous controlled ovarian stimulation cycle using a gonadotropin starting dose of 150 IU/day or higher. Poor response is defined as <4 oocytes retrieved, or cycle cancellation prior to oocyte retrieval due to inadequate follicular development.
- •Excessive ovarian response in a previous controlled ovarian stimulation cycle for IVF/ICSI using a daily FSH/hMG dose of ≤225 IU, defined as ≥25 oocytes retrieved or cycle cancellation prior to oocyte retrieval due to excessive ovarian response, including risk of ovarian hyperstimulation syndrome (OHSS).
- •Severe OHSS in a previous controlled ovarian stimulation cycle.
研究组 & 干预措施
Dose 2 of FE 999302
Experimental
Subcutaneous injection of Dose 2 of FE 999302 as a single dose.
干预措施: FE 999302 (Drug)
Dose 1 of FE 999302
Experimental
Subcutaneous injection of Dose 1 of FE 999302 as a single dose.
干预措施: FE 999302 (Drug)
Dose 3 of FE 999302
Experimental
Subcutaneous injection of Dose 3 of FE 999302 as a single dose.
干预措施: FE 999302 (Drug)
250 μg OVITRELLE
Active Comparator
Subcutaneous injection of 250 μg of OVITRELLE. 0.5 mL as a single dose.
干预措施: Ovitrelle (Drug)
10,000 IU NOVAREL
Active Comparator
Subcutaneous injection of 10,000 IU NOVAREL.
1 mL as a single dose.
干预措施: Novarel (Drug)
结局指标
主要结局
Number of metaphase II (MII) oocytes
时间窗: On the day of oocyte retrieval (2 days after triggering)
次要结局
- Number of oocytes retrieved(On the day of oocyte retrieval (2 days after triggering))
- Number of fertilised (2 pronuclei) oocytes(On day 1 insemination (3 days after triggering))
- Number and quality of embryos on day 3 after oocyte retrieval(Day 3 after insemination (5 days after triggering))
- Number and quality of blastocysts on day 5 after oocyte retrieval(Day 5 after insemination (7 days after triggering))
- Serum hormone concentrations of progesterone(Blood samples for analysis of circulating concentrations of progesterone will be drawn at several visits from day of triggering up to 22 days after triggering)
- Serum hormone concentrations of 17-OH-progesterone(Blood samples for analysis of circulating concentrations of 17-OH-progesterone will be drawn at several visits from day of triggering up to 22 days after triggering)
- Serum hormone concentrations of estradiol(Blood samples for analysis of circulating concentrations of estradiol will be drawn at several visits from day of triggering up to 22 days after triggering)
- Serum hormone concentrations of follicle stimulating hormone (FSH)(Blood samples for analysis of circulating concentrations of follicle stimulating hormone (FSH) will be drawn at several visits from day of triggering up to 22 days after triggering)
- Serum hormone concentrations of luteinising hormone (LH)(Blood samples for analysis of circulating concentrations of luteinising hormone (LH) will be drawn at several visits from day of triggering up to 22 days after triggering)
- Positive βhCG (positive serum βhCG test 13-15 days after transfer)(20-22 days after triggering)
- Clinical pregnancy (at least one gestational sac 5-6 weeks after transfer)(6-7 weeks after triggering)
- Vital pregnancy (at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after transfer)(6-7 weeks after triggering)
- Ongoing pregnancy (at least one intrauterine viable fetus 10-11 weeks after transfer)(11-12 weeks after triggering)
- Serum hCG concentrations at end-of-stimulation, the day after triggering, at oocyte retrieval, on day 5 after oocyte retrieval (transfer), and on day 7-9 after oocyte retrieval (mid luteal phase)(Blood samples for analysis of circulating concentrations of hCG will be drawn at several visits from day of triggering up to 9-11 days after triggering)
- Ovarian hyperstimulation syndrome (OHSS), overall and by timing, grade, and severity(≤9 days after triggering of final follicular maturation (early OHSS), >9 days after triggering of final follicular maturation (late OHSS))
- Injection site reactions (redness, pain, itching, swelling, and bruising) assessed by the subject following administration of investigational medicinal product (IMP)(Immediately, 30 minutes, and 24 hours after injection)
- Treatment-induced anti-hCG antibodies, overall as well as with neutralising capacity(Day of triggering up until 19-28 days after triggering)
- Multi-fetal gestation(From day after blastocyst transfer (7 days after triggering) up until ongoing pregnancy (11-12 weeks after triggering))
- Biochemical pregnancy(From day after blastocyst transfer (7 days after triggering) up until ongoing pregnancy (11-12 weeks after triggering))
- Spontaneous abortion(From day after blastocyst transfer (7 days after triggering) up until ongoing pregnancy (11-12 weeks after triggering))
- Ectopic pregnancy (with and without medical/surgical intervention)(From day after blastocyst transfer (7 days after triggering) up until ongoing pregnancy (11-12 weeks after triggering))
- Vanishing twins(From day after blastocyst transfer (7 days after triggering) up until ongoing pregnancy (11-12 weeks after triggering))
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaNCT06332092Fulgent Pharma LLC.46
已完成
2 期
A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.Controlled Ovarian StimulationNCT03564509Ferring Pharmaceuticals620
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and DyslipidemiaEssential Hypertension, DyslipidemiaNCT03338426Boryung Pharmaceutical Co., Ltd133
已完成
3 期
Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and DyslipidemiaEssential HypertensionDyslipidemiaNCT03156842Boryung Pharmaceutical Co., Ltd138
已完成
3 期
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic CirrhosisAwaiting Organ TransplantCirrhosisHepatitis BNCT01884415Fundación Pública Andaluza para la gestión de la Investigación en Sevilla112